文献速递乳腺癌放疗

BOOG 2013-08试验中保乳术后放疗的质量保证分析

Quality assurance of radiation therapy after breast-conserving surgery among patients in the BOOG 2013-08 trial.
PubMed 文献 · Radiother Oncol · 2023-12-21

BOOG 2013-08试验将cT1-2N0乳腺癌患者随机分为保乳手术联合或不联合前哨淋巴结活检后全乳放疗;本质量保证分析显示98.5%患者按方案放疗,区域放疗占5.9%,腋窝I级 incidental PTV 平均剂量为处方乳腺剂量的59.5%,两治疗组间无统计学或临床显著差异。

要点

  • 1,439/1,461例(98.5%)按放疗方案治疗,87例(5.9%)接受区域放疗。
  • 亚组326例中腋窝I级 incidental PTV 平均剂量为处方乳腺放疗剂量的59.5%。
  • 5例(1.5%)腋窝I级平均PTV剂量≥处方乳腺剂量的95%。

核心结论

  • BOOG 2013-08试验中放疗方案依从性高, incidental 腋窝放疗剂量低。
  • 两治疗组主要终点潜在差异不能归因于腋窝放疗剂量不同。

研究设计与样本

  • BOOG 2013-08试验(NCT02271828)将cT1-2N0乳腺癌患者随机分为保乳手术联合或不联合前哨淋巴结活检后全乳放疗。
  • 患者于2015年至2022年入组,记录处方放疗及25%入组患者的PTV参数,比较腋窝I-IV级剂量。
  • 采用多变量线性回归分析确定 incidental 腋窝放疗剂量的预后变量。

主要发现

  • 1,439/1,461例(98.5%)按方案治疗,87例(5.9%)接受区域放疗(SLNB组10.9%,no-SLNB组1.5%)。
  • 亚组326例中腋窝I级 incidental PTV 平均剂量为处方乳腺放疗剂量的59.5%。
  • 5例(1.5%)腋窝I级平均PTV剂量≥处方乳腺剂量的95%。
  • 两治疗组间 incidental 腋窝放疗剂量无统计学或临床显著差异。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND PURPOSE: In the BOOG 2013-08 trial (NCT02271828), cT1-2N0 breast cancer patients were randomized between breast conserving surgery with or without sentinel lymph node biopsy (SLNB) followed by whole breast radiotherapy (WBRT). While awaiting primary endpoint results (axillary recurrence rate), this study aims to perform a quality assurance analysis on protocol adherence and (incidental) axillary radiation therapy (RT) dose. MATERIALS AND METHODS: Patients were enrolled between 2015 and 2022. Data on prescribed RT and (in 25% of included patients) planning target volumes (PTV) parameters were recorded for axillary levels I-IV and compared between treatment arms. Multivariable linear regression analysis was performed to determine prognostic variables for incidental axillary RT dose. RESULTS: 1,439/1,461 included patients (98.5%) were treated according to protocol and 87 patients (5.9%) received regional RT (SLNB 10.9%, no-SLNB 1.5 %). In 326 patients included in the subgroup analysis, the mean incidental PTV dose at axilla level I was 59.5% of the prescribed breast RT dose. In 5 patients (1.5%) the mean PTV dose at level I was ≥95% of the prescribed breast dose. No statistically or clinically significant differences regarding incidental axillary RT dose were found between treatment arms. Tumour bed boost (yes/no) was associated with a higher incidental mean dose in level I (R2 = 0.035, F(6, 263) = 1.532, p 0.168). CONCLUSION: The results indicate that RT-protocol adherence was high, and that incidental axillary RT dose was low in the BOOG 2013-08 trial. Potential differences between treatmentarms regarding the primary endpoint can thus not be attributed to different axillary radiation doses.

来源:Radiother Oncol,查看原文。版权归原作者所有。

引用

  1. Wintraecken VM, Boersma LJ, van Roozendaal LM, et al. Quality assurance of radiation therapy after breast-conserving surgery among patients in the BOOG 2013-08 trial. Radiother Oncol. 2023. PMID: 38141879. doi:10.1016/j.radonc.2023.110069

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。